Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086034 · ClinicalTrials.gov registry record · Phase 2
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00086034: Completed Phase 2 study, sponsored by Pharmacyclics.
NCT00086034 is a Phase 2 study that has completed, run by Pharmacyclics. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086034, a Phase 2 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
Interventions
- DRUG Motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Phase | Phase 2 |
What the finished NCT00086034 record still lists
NCT00086034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Motexafin gadolinium is the first listed.
NCT00086034 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00086034 about?
NCT00086034 is a clinical study titled "Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma". The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
What is the current status of trial NCT00086034?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants.
What interventions are being tested in trial NCT00086034?
The interventions under investigation include: Motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00086034?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00086034's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT